TCGA-AC-A2QH-01B-04R-A22O-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 34
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.390
- MITOTIC_SPINDLE+0.300
- E2F_TARGETS+0.270
- UV_RESPONSE_DN+0.270
- WNT_BETA_CATENIN_SIGNALING+0.260
- HEDGEHOG_SIGNALING+0.250
- SPERMATOGENESIS+0.210
- NOTCH_SIGNALING+0.180
- TGF_BETA_SIGNALING+0.090
- MYC_TARGETS_V2+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- ESTROGEN_RESPONSE_LATE-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- OXIDATIVE_PHOSPHORYLATION-0.520
- ESTROGEN_RESPONSE_EARLY-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- ADIPOGENESIS-0.460
- ALLOGRAFT_REJECTION-0.450
- P53_PATHWAY-0.450
- IL6_JAK_STAT3_SIGNALING-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0122214 | — | — | 0.931 |
| 2 | SRR2932838 | — | — | 0.913 |
| 3 | ERR2208889 | — | — | 0.909 |
| 4 | TCGA-CR-7370-01A-11R-2132-07 | — | — | 0.905 |
| 5 | SRR6013547 | — | cohortMD1 | 0.898 |
| 6 | TCGA-AC-A2QH-01A-11R-A18M-07 | — | D | 0.894 |
| 7 | SRR10899974 | — | — | 0.891 |
| 8 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.885 |
| 9 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.882 |
| 10 | 20130253.TNBC | — | E | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |